OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin, Kun Ke, Leye Yan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Long-Wang Lin, Kun Ke, Leye Yan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Showing 11 citing articles:
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
Lingfeng Diao, Chendong Wang, Ran You, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 4, pp. 746-753
Closed Access | Times Cited: 10
Lingfeng Diao, Chendong Wang, Ran You, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 4, pp. 746-753
Closed Access | Times Cited: 10
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
Yufeng Zhang, Haiyan Zhang, Haoqian Xu, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Yufeng Zhang, Haiyan Zhang, Haoqian Xu, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
Lingling Zhao, Cheng Xu, Jiewen Deng, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Lingling Zhao, Cheng Xu, Jiewen Deng, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review
Ying Wu, Zhimin Zeng, Shuanggang Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Ying Wu, Zhimin Zeng, Shuanggang Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The Value of Hepatic Artery Infusion Chemotherapy (HAIC) in the Treatment of Patients with Hepatocellular Carcinoma (HCC) Resistant to Transcatheter Arterial Chemoembolization (TACE)
鹏 蒋
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 324-330
Closed Access
鹏 蒋
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 324-330
Closed Access
Evaluation of 3-O-β-D-galactosylated resveratrol-loaded polydopamine nanoparticles for hepatocellular carcinoma treatment
Xiaoxiao Shan, Shujie Lv, Hongyan Cheng, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 203, pp. 114454-114454
Closed Access | Times Cited: 2
Xiaoxiao Shan, Shujie Lv, Hongyan Cheng, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 203, pp. 114454-114454
Closed Access | Times Cited: 2
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13715-13715
Open Access | Times Cited: 6
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13715-13715
Open Access | Times Cited: 6
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes
Phan Nhan Hien, Ho Jong Chun, Jung Suk Oh, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 2, pp. 721-729
Open Access | Times Cited: 1
Phan Nhan Hien, Ho Jong Chun, Jung Suk Oh, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 2, pp. 721-729
Open Access | Times Cited: 1
Combined transarterial therapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Cheng Zhang, Yuyan Xu, Lei Cai, et al.
Research Square (Research Square) (2024)
Open Access
Cheng Zhang, Yuyan Xu, Lei Cai, et al.
Research Square (Research Square) (2024)
Open Access
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review)
Ganghui Ye, Meng Ye, Xin Jin
American Journal of Cancer Research (2024) Vol. 14, Iss. 9, pp. 4113-4171
Closed Access
Ganghui Ye, Meng Ye, Xin Jin
American Journal of Cancer Research (2024) Vol. 14, Iss. 9, pp. 4113-4171
Closed Access
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
Min Wei, P H Zhang, Chao Feng Yang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Min Wei, P H Zhang, Chao Feng Yang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
